Reduced radiosensitivity and increased CD40 expression in cyclophosphamide-resistant subclones established from human cervical squamous cell carcinoma cells

Oncol Rep. 2005 Oct;14(4):941-8.

Abstract

To investigate the interaction between anticancer drug resistance and radioresistance in cervical cancer cells, 3 single cell-derived cyclophosphamide-resistant subclones were established from the drug- and radiosensitive human cervical squamous cell carcinoma cell line ME180 by chronic exposure cultures with 4-hydroxy-cyclophosphamide followed by limiting dilution. The established cyclophosphamide-resistant subclones were also radio- and multidrug-resistant to 7 other anticancer drugs. Flow cytometric analysis revealed significantly increased levels of CD40 expression on the 3 resistant subclones, whereas no CD40 expression was found on the parent ME180 cells. However, there were no changes in the expression levels of CD29, CD49a-CD49f or CD59 between the parent cells and resistant subclones. A recombinant human soluble CD40 ligand had no effect on the proliferation of the resistant subclones. Irradiation had no effect on the 4-hydroxy-cyclophosphamide sensitivity of the parent cells. These results indicate that the established cyclophosphamide-resistant subclones have impaired cell death signals, which are common to both drug- and radiation-induced apoptosis, and cyclophosphamide may not be an adequate drug for use in concurrent chemoradiotherapy. Furthermore, CD40 activation signals may be associated with the multidrug- and radioresistance in these cyclophosphamide-resistant subclones.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents, Alkylating / pharmacology*
  • Bleomycin / pharmacology
  • CD40 Antigens / biosynthesis*
  • CD40 Ligand / metabolism
  • CD59 Antigens / biosynthesis
  • Carcinoma, Squamous Cell / drug therapy*
  • Cell Line, Tumor
  • Cell Proliferation
  • Cyclophosphamide / analogs & derivatives
  • Cyclophosphamide / metabolism
  • Cyclophosphamide / pharmacology
  • Cyclophosphamide / therapeutic use*
  • Dose-Response Relationship, Drug
  • Dose-Response Relationship, Radiation
  • Drug Resistance, Multiple
  • Drug Resistance, Neoplasm*
  • Female
  • Flow Cytometry
  • Gamma Rays
  • Humans
  • Integrin alpha1 / biosynthesis
  • Integrin alpha2 / biosynthesis
  • Integrin alpha3 / biosynthesis
  • Integrin alpha4 / biosynthesis
  • Integrin alpha5 / biosynthesis
  • Integrin alpha6 / biosynthesis
  • Integrin beta1 / biosynthesis
  • Radiation Tolerance
  • Uterine Cervical Neoplasms / drug therapy*

Substances

  • Antineoplastic Agents
  • Antineoplastic Agents, Alkylating
  • CD40 Antigens
  • CD59 Antigens
  • Integrin alpha1
  • Integrin alpha2
  • Integrin alpha3
  • Integrin alpha5
  • Integrin alpha6
  • Integrin beta1
  • Bleomycin
  • Integrin alpha4
  • CD40 Ligand
  • 4-hydroxycyclophosphamide
  • Cyclophosphamide